(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 August 2010 (05.08.2010)

PCT

(10) International Publication Number
WO 2010/088444 A1

(51) International Patent Classification:
A61K 39/395 (2006.01) *C07K 16/24* (2006.01)

(21) International Application Number:
PCT/US2010/022478

(22) International Filing Date:
29 January 2010 (29.01.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/148,106 29 January 2009 (29.01.2009) US
61/184,182 4 June 2009 (04.06.2009) US

(71) Applicant *(for all designated States except US)*: **MEDIMMUNE, LLC** [US/US]; One Medimmune Way, Gaithersburg, MD 20878 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BOWEN, Michael** [US/US]; 7812 Polara Place, Rockville, MD 20855 (US). **WU, Herren** [US/US]; 14405 Harvest Moon Road, Boyds, MD (US). **DALL'ACQUA, William** [FR/US]; 564 Chestertown Street, Gaithersburg, MD 20878 (US). **KIENER, Peter** [US/US]; 14017 Gorky Drive, Potomac, MD 20854 (US). **JALLAL, Bahija** [US/US]; 1116 Smokey Quartz, Potomac, MD 20854 (US). **COYLE, Anthony** [GB/US]; 1155 23rd Street, Washington, DC 20037 (US).

(74) Agents: **HOLMES-SON, Michelle** et al.; Medimmune, LLC, One MedImmune Way, Gaithersburg, MD 20878 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2010/088444 A1

(54) **Title**: HUMAN ANTI-IL-6 ANTIBODIES WITH EXTENDED IN VIVO HALF-LIFE AND THEIR USE IN TREATMENT OF ONCOLOGY, AUTOIMMUNE DISEASES AND INFLAMMATORY DISEASES

(57) **Abstract**: The present invention provides human anti-IL-6 antibodies with extended in vivo half-life. The invention further relates to pharmaceutical compositions, therapeutic compositions, and methods using therapeutic antibodies that bind to IL-6 and that has an extended in vivo half-life for the treatment and prevention of IL-6 mediated diseases and disorders, such as, but not limited to, inflammatory diseases and disorders, autoimmune diseases and disorders and tumors.